Targeted Therapy of Acute Myeloid Leukemia. This item is unavailable.
Language: English
Published by Springer, 2016
- Softcover
- New

Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH
AbeBooks seller since August 14, 2006
Condition: New
£ 195.47
Item description from seller
Druck auf Anfrage Neuware - Printed after ordering - This book provides an unprecedented overview of 'Targeted Therapies' for acute myeloid leukemias. It aims at an almost comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Paired and authoritative chapters by leading research scientists and clinicians explain basic concepts and clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML, the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53 and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. Chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells and leukemia metabolism provide insights into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies round up this overview of the multi-dimensional therapeutic landscape in which leukemia specialists develop treatment strategies that are expected to make 'leukemia history' in the near future.…
Seller Inventory # 9781493939893
- Title
- Targeted Therapy of Acute Myeloid Leukemia
- Author
- Michael Andreeff
- Publisher
- Springer
- Publication year
- 2016
- Condition
- Neu
- Binding
- Taschenbuch
- Language
- English
- ISBN 10
- 1493939890
- ISBN 13
- 9781493939893
- Item weight
- 1,258 grams
- Dimensions
- 235x155x46 mm
- Series
- Book 12 of 24: Current Cancer Research
"Synopsis" may belong to another edition of this title.
From the Back Cover
This book provides an unprecedented overview of targeted therapies for acute myeloid leukemias. The volume provides comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Authoritative chapters are written by leading research scientists and clinicians, who explain basic concepts and the clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML. The chapter topics include the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53, and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. In addition, chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells, and leukemia metabolism, provide insight into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies complete the overview of the multi-dimensional therapeutic landscape, where leukemia specialists develop treatment strategies, which are expected to bring forth critical breakthroughs in the field of leukemia.
"About the title" may belong to another edition of this title.